US 12,433,904 B2
Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
Derek John Londesbrough, Hartlepool (GB); Christopher Brown, Gateshead (GB); Julian Scott Northen, South Shields (GB); Gillian Moore, Sedgefield (GB); Hemant Kashinath Patil, Surrey (GB); David E. Nichols, Chapel Hill, NC (US); Hans Ake Eriksson, Altrincham (GB); George Goldsmith, Altrincham (GB); Ekaterina Malievskaia, Altrincham (GB); Manon Cecile Elisabeth Veraart, Altrincham (GB); and Lars Christian Wilde, Altrincham (GB)
Assigned to Compass Pathfinder Limited, Altrincham (GB)
Appl. No. 17/604,619
Filed by COMPASS PATHFINDER LIMITED, Altrincham (GB)
PCT Filed Apr. 17, 2020, PCT No. PCT/IB2020/053687
§ 371(c)(1), (2) Date Oct. 18, 2021,
PCT Pub. No. WO2020/212951, PCT Pub. Date Oct. 22, 2020.
Claims priority of provisional application 62/946,159, filed on Dec. 10, 2019.
Claims priority of provisional application 62/893,611, filed on Aug. 29, 2019.
Claims priority of provisional application 62/893,110, filed on Aug. 28, 2019.
Claims priority of provisional application 62/835,476, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,450, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,477, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,474, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,478, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,465, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,449, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,482, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,481, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,460, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,479, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,480, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,458, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,484, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,472, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,464, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,485, filed on Apr. 17, 2019.
Prior Publication US 2023/0000883 A1, Jan. 5, 2023
Int. Cl. A61K 31/675 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/661 (2006.01); A61P 25/00 (2006.01); A61P 25/04 (2006.01); A61P 25/08 (2006.01); A61P 25/16 (2006.01); A61P 25/20 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); C07F 9/572 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/661 (2013.01); A61P 25/00 (2018.01); A61P 25/04 (2018.01); A61P 25/08 (2018.01); A61P 25/16 (2018.01); A61P 25/20 (2018.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01); C07F 9/5728 (2013.01); C07B 2200/13 (2013.01)] 32 Claims
 
1. A method of treating a migraine in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of psilocybin, wherein the psilocybin comprises crystalline psilocybin characterized by X-ray powder diffraction (XRPD) peaks at 11.5±0.1, 12.0±0.1, 14.5±0.1, 17.5±0.1 and 19.7±0.1°2θ, and wherein the crystalline psilocybin has a chemical purity of greater than 97% as determined by HPLC analysis.